Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2- Targeted and TROP-2–Targeted Therapy

Learn how the experts integrate precision therapy into the treatment algorithm for patients with HER2-low, HR-positive and triple-negative breast cancer in this program centered around a dynamic live symposium at ASCO 2023. Download slides, watch the on-demand webcast, and read an expert-authored commentary summarizing the key learning points from the live symposium for use in your clinic.

Share

Program Content

Activities

Treatment of HER2-Low Breast Cancer
Establishing HER2-Targeted Therapies in the Treatment of HER2-Low Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

TROP-2 in breast cancer
Incorporating TROP-2–Targeted Therapies Into the Breast Cancer Landscape
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

ADC-Associated AEs
Practical Adverse Event Management for Optimal Therapeutic Outcomes
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2023

Activities

HER2- and TROP-2–Targeted Tx in Breast Cancer
Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 20, 2023

Expires: June 19, 2024

Activities

FAQs: ADCs in Breast Cancer
FAQs: The Expanding Role of Antibody–Drug Conjugates in Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 21, 2023

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.